Multifactorial treatment by means of blood glucose and blood pressure control, including maximum doses of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), as well as administration of lipid lowering drugs, is an efficient, though insufficient, approach to treatment for diabetic nephropathy (DN)1. Here, ACE is linked to liver dysplastic nodule.